glp 1 agonist effects GLP-1 and Anesthesia: Considerations and Cautions for CRNAs Glucagon-Like Peptide-1: New Regulator in

As shown in Scheme 10

[DOI] [PubMed] [Google Scholar] 54.Henriksen K, Broekhuizen K, de Boon WM, Karsdal MA, Bihlet AR, Christiansen C, et al

These include the hypothalamus, VTA, and nucleus accumbens

The explosion of GLP-1 media coverage has created confusion about what falls under the GLP-1 umbrella

Specifically, prolonged GLP-1RA administration (13 years or longer) has been associated with elevated thyroid cancer risk in certain populations [4], while high concentrations of liraglutide (100 nM) have been demonstrated to promote breast cancer progression via the NOX4/ROS/VEGF signaling pathway [18]

A few GLP-1 agonists currently in phase 3 trials are higher-dose injectable semaglutide 7.2 mg (Novo Nordisk), oral semaglutide 50 mg (Novo Nordisk) and orforglipron (Eli Lilly)